Overview

A Study to Investigate the Safety, Tolerability, and Processing by the Body of Intravenous RO7121932 in Participants With Multiple Sclerosis

Status:
Recruiting
Trial end date:
2025-01-31
Target enrollment:
Participant gender:
Summary
The primary purpose of the study is to evaluate the safety and tolerability of single ascending intravenous (IV) doses of RO7121932 in participants with multiple sclerosis (MS)
Phase:
Phase 1
Details
Lead Sponsor:
Hoffmann-La Roche